Cargando…
Chemotherapy negatively impacts the tumor immune microenvironment in NSCLC: an analysis of pre- and post-treatment biopsies in the multi-center SAKK19/09 study
BACKGROUND: Over the past few years, immune checkpoint inhibitors have changed the therapeutic landscape of non-small-cell lung cancer (NSCLC). Response to immune checkpoint inhibitors correlates with a pre-existing anti-tumoral immune response. Checkpoint inhibitors have been introduced as second-l...
Autores principales: | Amrein, M. A., Bührer, E. D., Amrein, M. L., Li, Q., Rothschild, S., Riether, C., Jaggi, R., Savic-Prince, S., Bubendorf, L., Gautschi, O., Ochsenbein, A. F. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7889678/ https://www.ncbi.nlm.nih.gov/pubmed/32767058 http://dx.doi.org/10.1007/s00262-020-02688-4 |
Ejemplares similares
-
P1343: TNIK SIGNALLING IMPAIRS SELF-RENEWAL AND LONG-TERM RECONSTITUTION CAPACITY OF HSCS
por: Palombella, Luca, et al.
Publicado: (2023) -
Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials
por: König, D., et al.
Publicado: (2022) -
Cytotoxic T cells induce proliferation of chronic myeloid leukemia stem cells by secreting interferon-γ
por: Schürch, Christian, et al.
Publicado: (2013) -
Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08)
por: Curioni-Fontecedro, Alessandra, et al.
Publicado: (2019) -
Tumor Initiation Capacity and Therapy Resistance Are Differential Features of EMT-Related Subpopulations in the NSCLC Cell Line A549()
por: Tièche, Colin Charles, et al.
Publicado: (2018)